Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Tuesday.

According to Zacks, “Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company’s product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton, New Jersey. “

Separately, ValuEngine lowered Bellerophon Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, June 10th.

Shares of Bellerophon Therapeutics (NASDAQ BLPH) traded down 1.80% during mid-day trading on Tuesday, reaching $1.09. The company had a trading volume of 142,300 shares. The stock’s market capitalization is $38.71 million. The firm has a 50 day moving average of $1.32 and a 200-day moving average of $1.33. Bellerophon Therapeutics has a one year low of $0.43 and a one year high of $1.98.

Bellerophon Therapeutics (NASDAQ:BLPH) last released its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.03. Analysts forecast that Bellerophon Therapeutics will post ($1.12) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Zacks Investment Research Downgrades Bellerophon Therapeutics, Inc. (BLPH) to Hold” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/zacks-investment-research-downgrades-bellerophon-therapeutics-inc-blph-to-hold/1516337.html.

Several institutional investors have recently added to or reduced their stakes in the company. Susquehanna International Group LLP acquired a new position in Bellerophon Therapeutics during the second quarter worth $1,316,000. Vanguard Group Inc. raised its position in Bellerophon Therapeutics by 52.6% in the second quarter. Vanguard Group Inc. now owns 612,641 shares of the biotechnology company’s stock worth $821,000 after buying an additional 211,111 shares during the period. Goldman Sachs Group Inc. acquired a new position in Bellerophon Therapeutics during the first quarter worth $125,000. Finally, Renaissance Technologies LLC raised its position in Bellerophon Therapeutics by 99.7% in the first quarter. Renaissance Technologies LLC now owns 477,400 shares of the biotechnology company’s stock worth $711,000 after buying an additional 238,300 shares during the period. 42.11% of the stock is owned by hedge funds and other institutional investors.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.

Receive News & Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.